Current and Future Role of Medical Imaging in Guiding the Management of Patients With Relapsed and Refractory Non-Hodgkin Lymphoma Treated With CAR T-Cell Therapy

Current and Future Role of Medical Imaging in Guiding the Management of Patients With Relapsed and Refractory Non-Hodgkin Lymphoma Treated With CAR T-Cell Therapy

Chimeric antigen receptor (CAR) T-cells are a novel immunotherapy available for patients with refractory/relapsed non-Hodgkin lymphoma. In this indication, clinical trials have demonstrated that CAR T-cells achieve high rates of response, complete response, and long-term response (up to 80%, 60%, an...

Full description

Bibliographic Details
Main Authors: Laetitia Vercellino, Dorine de Jong, Roberta di Blasi, Salim Kanoun, Ran Reshef, Lawrence H. Schwartz, Laurent Dercle
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-05-01
Series:Frontiers in Oncology
Subjects:
lymphoma
CAR T-cell
immunotherapy
FDG PET/CT
CT scan
prognostic biomarker
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.664688/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2021.664688/full

Similar Items